drugset
drugset / Trial / NCT05932459

A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension

NCT05932459 ↗

Phase 1 Completed 38 enrolled Vigonvita Life Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is divided into three parts: bioavailability study (hereinafter referred to as "BA study"), food effect study (hereinafter referred to as "FE study") and pharmacokinetic characteristics study (hereinafter referred to as "PK characteristics study"). A total of 38 subjects are planned to be enrolled. The three parts of the study can be carried out simultaneously, and there is no order requirement. The subjects will be assigned to one of them according to the enrollment order. Dose selection is 100mg, 300mg and 25mg.

Timeline

Start
2023-07-09
Primary completion
2023-09-04
Completion
2023-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject REMIDEVIR Small molecule 25 mg Oral
Subject REMIDEVIR Small molecule 100 mg Oral
Subject REMIDEVIR Small molecule 300 mg Oral

Indications

No indication recorded.